Erlotinib

Recent Results in Cancer Research

Volumn 184, Issue , 2010, Pages 21-31

  Steins, M ^a   Thomas, M ^a   Geissler M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE; SORAFENIB;

ACNE; BILE DUCT CANCER; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; ECZEMA; ENDOMETRIUM CANCER; ENZYME INHIBITION; FATIGUE; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; META ANALYSIS; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; RASH; REVIEW; SEPSIS; STOMACH CANCER; STOMATITIS; SYSTEMATIC REVIEW; XEROSIS;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; NEOPLASMS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77953674304     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-01222-8_2     Document Type: Review

References (65)

1. Alroy I, Yarden Y (1997) The Erb B signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligandreceptor interactions. FEBS Lett 410:83-86
2. Arteaga CL (2002) Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 29 (5 Suppl14):3-9
3. Bezjak A, Tu D, Seymour L et al (2006) Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study Br. J Clin Oncol 24:3831-3837
4. Birk D, Gansauge F, Gansauge S (1999) Serum and correspondent tissue measurements of epidermal growth factor (EGF) and epidermal growth factor receptor (EGF-R). Clinical relevance in pancreatic cancer and chronic pancreatitis. Int J Pancreatol 25:89-96
5. Boeck S, Hausmann A, Reibke R et al (2007) Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs 18:1109-1111
6. Brabender J, Danenberg KD, Metzger R et al (2001) Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7: 1850-1855
7. Bramhall SR, Schulz J, Nemunaitis J (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161-167
8. Buckley AF, Burgart LJ, Sahai V et al (2008) Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 129: 245-251
9. Burris HA 3rd, Moore MJ, Andersen J (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
10. Cedrés S, Prat A, Martínez P et al (2009) Clinical surrogate markers of survival in advanced nonsmall cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer, in Press
11. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34
12. Chiang D, Villanueva A, Peix J (2008) Focal VEGFA amplifications and molecular classification of hepatocellular carcinoma. Cancer Res 68: 6779-6788
13. Clark GM, Zborowski DM, Santabarbara P et al (2006) Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with nonsmall-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 7:389-394
14. Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M (2006) Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer 51:89-96
15. Duffy A, Kortmansky J, Schwartz GK et al (2008) A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 19:86-91
16. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745-750
17. Epelbaum R, Schnaider J, Gluzman A (2007) Erlotinib as a single-agent therapy in patients with advanced pancreatic cancer. ASCO Gastrointestinal Cancer Symposium, Orlando, FL, 19-21 January 2007
18. Fukuoka M, Yano S, Giaccone G et al (2003) Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246
19. Gatzemeier U, Pluzanska A, Szczesna A et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced nonsmall-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 25:1545-1552
20. Giaccone G (2004) The role of gefitinib in lung cancer treatment. Clin Cancer Res 10:4233s-4237s
21. Herbst RS, Prager D, Hermann R et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced nonsmall-cell lung cancer. J Clin Oncol 23: 5892-5899
22. Huether A, Hopfner M, Sutter AP et al (2006) Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World J Gastroenterol 12:5160-5167 (Pubitemid 44362047)
23. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354
24. Iannitti D, Dipetrillo T, Akerman P (2005) Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 28:570-575
25. Kindler H, Niedzwiecki D, Hollis D (2007) A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (Pts) with advanced pancreatic cancer (PC): a preliminary analysis of cancer and leukemia group B (CALGB) 80303. J Clin Oncol 25(Suppl 18):4508
26. Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149-2158
27. Kulke MH, Blaszkowsky LS, Ryan DP et al (2007) Capecitabine plus erlotinib in gemcitabinerefractory advanced pancreatic cancer. J Clin Oncol 25:4787-4792
28. Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329-338
29. Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312-1327
30. Llovet JM, Ricci S, Mazzaferro V et al, SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
31. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
32. Lynch TJ Jr, Kim ES, Eaby B (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610-621
33. Marchetti A, Martella C, Felicioni L et al (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857-865
34. Mok T, Wu Y-L, Thongprasert S et al (2008) Phase III, randomised, open-label, first-line study of gefitinib (G) vs. carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non-small-cell lung cancer (NSCLC) (IPASS). Ann Oncol 19(Suppl 8):viii1
35. Moore MJ, Goldstein D, Hamm J (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966
36. Moore MJ, Hamm J, Dancey J (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3296-3302
37. Natale RB (2004) Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer. Sem Oncol 31(3 Suppl 9):23-30
38. Neuhaus P, Riess H, Post S et al (2008) CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 26:abstr. LBA4504
39. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9-S15
40. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500
41. Parkin DM, Bray F, Ferlay J (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
42. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311
43. Pao W, Miller VA (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol 23:2556-2568
44. Pelzer U, Kubica K, Stieler J et al (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26 (Suppl):abstr 4508
45. Pérez-Soler R, Chachoua A, Hammond LA et al (2004) Determants of tumour response and survival with erlotinib in patients with non-smallcell lung cancer: a randomized trial. J Clin Oncol 22:3238-3247
46. Pérez-Soler R (2006) Rash as a surrogate marker for efficacy of epidermal growth factor inhibitors in lung cancer. Clin Lung Cancer 8(Suppl 1): S7-14
47. Philip PA, Benedetti J, Fenoglio-Preiser C (2007) Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (Pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC) SWOG S0205 study. J Clin Oncol 25(Suppl 18):abstr LBA4509
48. Philip PA, Mahoney MR, Allmer C (2005) Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23: 6657-6663
49. Schneider G, Hamacher R, Eser S et al (2008) Molecular biology of pancreatic cancer - new aspects and targets. Anticancer Res 28(3A): 1541-1550
50. Saif MW, Merikas I, Tsimboukis S et al (2008) Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP 9:267-274
51. Salomon DS, Brandt R, Ciardiello F et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232
52. Sandler AB (2006) Nondermatologic adverse events associated with anti-EGFR therapy. Oncology 20(5 Suppl 2):35-40
53. Shapiro J, Marshall J, Karasek P (2005) G17DT+gemcitabine (Gem) versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: results of a randomized, double-blind, multinational, multicenter study. J Clin Oncol 23(Suppl 16):4012
54. Shepherd FA, Pereira JR, Ciuleanu T et al for the National Cancer Institute of Canada Clinical Trails Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132
55. Sultana A, Smith CT, Cunningham D et al (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 20: 2607-2615
56. Tang PA, Tsao MS, Moore MJ (2006) A review of erlotinib and its clinical use. Expert Opin Pharmacother 7:177-193
57. Thomas MB, Chadha R, Glover K (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110: 1059-1067
58. Thomas MB, Morris JS, Chadha R et al (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27: 843-850
59. Tsao M-S, Sakurada A, Cutz J-C et al (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353: 133-144
60. Van Cutsem E, Van de Velde H, Karasek P (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22: 1430-1438
61. Van Cutsem E, Vervenne WL, Bennouna J et al (2009) Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: results from the AViTA study. ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, A117
62. Villanueva A, Newell P, Chiang D (2007) Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27:55-76
63. Wacker B, Nagrani T, Weinberg J et al (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913-3921
64. Xiong HQ, Abbruzzese JL (2002) Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 29(Suppl 14):31-37
65. Zhu C-Q, da Cunha Santos G, Ding K et al (2008) Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study Br. 21. J Clin Oncol 26:4268-4275